Q-omics provides the consensus-scored RPL7AP3 profile across patient tissues and cancer cell-line models. RPL7AP3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP3 is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, RPL7AP3 RNA expression shows 6,847 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight DLBC, STAD, and LUAD as cancer lineages where RPL7AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP3 survival associations across molecular data types. RPL7AP3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP3 RNA expression–survival associations across cancer types. High RPL7AP3 expression shows unfavorable associations in DLBC, KIRP and ACC, but favorable associations in READ, CESC and MESO. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RPL7AP3 RNA expression.
This table summarizes RPL7AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP3 shows lower tumor expression in UCEC and higher tumor expression in STAD, COAD, KIRP, READ and BLCA. The STAD box plot shows higher RPL7AP3 RNA expression in tumor versus normal tissue (log2 FC = +0.654, t-test p = .012).
This table shows molecular features associated with RPL7AP3 in patient tissues and cancer cell lines. In patient samples, RPL7AP3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
